Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Helwan University, Ain-Helwan, Helwan, Cairo, Egypt.
Med Chem. 2022;18(3):323-336. doi: 10.2174/1573406417666210604103135.
2-Furanones have attracted great attention due to their biological activities. They also have the ability to be converted to several biologically active heterocyclic and nonheterocyclic compounds, especially as anti-cancer agents.
This research aims to share in the development process of novel cytotoxic agents by synthesizing certain 2-furanone derivatives and using them as starting materials for the preparation of novel heterocyclic and non-heterocyclic compounds, then testing the synthesized derivatives for their anti-cancer activities.
All the newly synthesized compounds were fully characterized by elemental analysis, IR, Mass, and 1H-NMR spectroscopy. 18 synthesized compounds were selected by National Cancer Institute (NCI) for testing against 60 cell lines, and the active compound was tested as MAPK14 and VEGFR2-inhibitor using Staurosporine as standard.
Compound 3a showed the higher activity against several cell lines; Leukemia (SR), Non- Small Cell Lung Cancer (NCI-H460), colon cancer (HCT-116), ovarian cancer (OVCAR-4), renal cancer (786-0, ACHN and UO-31) and, finally breast cancer (T-47D). It also has better inhibition activity against MAPK14 than the used reference.
Compound 3a has promising anti-cancer activities compared to the used standards and may need further modification and investigations.
2-呋喃酮因其生物活性而受到广泛关注。它们还具有转化为几种具有生物活性的杂环和非杂环化合物的能力,特别是作为抗癌剂。
本研究旨在通过合成某些 2-呋喃酮衍生物并将其用作制备新型杂环和非杂环化合物的起始原料,分享新型细胞毒性剂的开发过程,然后测试合成衍生物的抗癌活性。
所有新合成的化合物均通过元素分析、IR、质量和 1H-NMR 光谱进行了充分表征。18 种合成化合物由国家癌症研究所 (NCI) 选择进行 60 种细胞系的测试,活性化合物作为 MAPK14 和 VEGFR2 抑制剂进行测试,以 Staurosporine 作为标准。
化合物 3a 对几种细胞系(白血病(SR)、非小细胞肺癌(NCI-H460)、结肠癌细胞(HCT-116)、卵巢癌细胞(OVCAR-4)、肾癌细胞(786-0、ACHN 和 UO-31)和乳腺癌(T-47D)表现出更高的活性。它对 MAPK14 的抑制活性也优于所用参考标准。
与所用标准相比,化合物 3a 具有有前途的抗癌活性,可能需要进一步的修饰和研究。